Published • loading... • Updated
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
- Akeso announced that the first patient was enrolled in COMPASSION-37, a global Phase III trial of cadonilimab plus chemotherapy for previously untreated, advanced HER2-negative gastric or gastroesophageal junction cancer.
- The trial will compare cadonilimab plus chemotherapy with chemotherapy alone or chemotherapy plus nivolumab while evaluating safety and effectiveness across diverse populations.
- The study is co-led by investigators from Memorial Sloan Kettering Cancer Center, Johannes Gutenberg University Mainz, and Peking University.
Insights by Ground AI
48 Articles
48 Articles
The Conway Daily Sun+47 Reposted by 47 other sources
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody,…
Coverage Details
Total News Sources48
Leaning Left6Leaning Right6Center29Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
15%
C 71%
14%
Factuality
To view factuality data please Upgrade to Premium
